Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126805142 | 12680514 | 2 | F | 201606 | 20160831 | 20160824 | 20160906 | EXP | PHHY2016BR115043 | NOVARTIS | 87.36 | YR | M | Y | 58.00000 | KG | 20160906 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126805142 | 12680514 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG, QD PATCH 5 (CM2) | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 126805142 | 12680514 | 2 | C | PROLOPA | BENSERAZIDELEVODOPA | 1 | Oral | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126805142 | 12680514 | 1 | Dementia |
| 126805142 | 12680514 | 2 | Parkinson's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126805142 | 12680514 | OT |
| 126805142 | 12680514 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126805142 | 12680514 | Malaise | |
| 126805142 | 12680514 | Parkinson's disease | |
| 126805142 | 12680514 | Pneumonia | |
| 126805142 | 12680514 | Pulmonary embolism | |
| 126805142 | 12680514 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |